Innoviva (INVA) Enterprise Value (2010 - 2026)
Innoviva's (INVA) quarterly Enterprise Value came in at -$603.1 million in Q1 2026, down 89.0% YoY from -$5.5 billion in Q1 2025, and down 9.46% on a QoQ basis from -$550.9 million in Q4 2025.
Analysis
Innoviva (INVA) Enterprise Value (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Enterprise Value data on file, last reported at -$603.1 million in Q1 2026.
- Quarterly Enterprise Value fell 89.0% year-over-year to -$603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$603.1 million (down 89.0% YoY) and the FY2025 annual result came in at -$550.9 million, down 80.66% from the prior year.
- Enterprise Value declined to -$603.1 million in Q1 2026, from -$550.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$144.0 million in Q1 2023 to a low of -$603.1 million in Q1 2026.
- A 5-year average of -$299.5 million and a median of -$283.6 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 1469.95% — and 2023, when it jumped 40.21%.
- Tracing INVA's Enterprise Value over 5 years: stood at -$291.0 million in 2022, then surged by 33.51% to -$193.5 million in 2023, then plunged by 57.59% to -$305.0 million in 2024, then sank by 80.66% to -$550.9 million in 2025, then retreated by 9.46% to -$603.1 million in 2026.
- The last three Enterprise Value figures came in at -$603.1 million (Q1 2026), -$550.9 million (Q4 2025), and -$476.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 925.31 Mn |
| Sep 30, 2025 | 831.43 Mn |
| Jun 30, 2025 | 768.16 Mn |
| Mar 31, 2025 | 691.16 Mn |
| Dec 31, 2024 | 674.74 Mn |
| Sep 30, 2024 | 948.20 Mn |
| Jun 30, 2024 | 809.01 Mn |
| Mar 31, 2024 | 778.67 Mn |
| Dec 31, 2023 | 821.93 Mn |
| Sep 30, 2023 | 656.35 Mn |
| Jun 30, 2023 | 657.29 Mn |
| Mar 31, 2023 | 596.47 Mn |
| Dec 31, 2022 | 625.69 Mn |
| Sep 30, 2022 | 509.03 Mn |
| Jun 30, 2022 | 745.28 Mn |
| Mar 31, 2022 | 1.13 Bn |
| Dec 31, 2021 | 1.11 Bn |
| Sep 30, 2021 | 1.12 Bn |